Clinical Trial Update: SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SI-B001 in combination with chemotherapy for EGFR/ALK wild-type recurrent or metastatic non-small cell lung cancer. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SI-B001

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING